{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:20:50Z","timestamp":1758633650591},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12325-023-02502-4","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T15:04:11Z","timestamp":1681398251000},"page":"2595-2625","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Clinical Cardiology 2022: A Summary of Key Clinical Trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Patrick","family":"Savage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnathan","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Menown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"6","key":"2502_CR1","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s12325-022-02136-y","volume":"39","author":"P Savage","year":"2022","unstructured":"Savage P, Cox B, Linden K, Coburn J, Shahmohammadi M, Menown I. Advances in clinical cardiology 2021: a summary of key clinical trials. Adv Ther. 2022;39(6):2398\u2013437. https:\/\/doi.org\/10.1007\/s12325-022-02136-y.","journal-title":"Adv Ther"},{"issue":"15","key":"2502_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","volume":"387","author":"P Perera","year":"2022","unstructured":"Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387(15):1351\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2206606","journal-title":"N Engl J Med"},{"key":"2502_CR3","unstructured":"Omerovic E, on behalf of the SCAAR investigators. Survival after PCI or CABG for left main coronary disease: a report from the Swedish Coronary Angiography and Angioplasty Registry. Presented at: TCT 2022. September 19, 2022. Boston, MA."},{"issue":"6","key":"2502_CR4","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1007\/s12325-020-01355-5","volume":"37","author":"K Linden","year":"2020","unstructured":"Linden K, Mailey J, Kearney A, Menown IBA. Advances in clinical cardiology 2019: a summary of key clinical trials. Adv Ther. 2020;37(6):2620\u201345. https:\/\/doi.org\/10.1007\/s12325-020-01355-5.","journal-title":"Adv Ther"},{"key":"2502_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.amjcard.2022.04.004","volume":"174","author":"T Woodhead","year":"2022","unstructured":"Woodhead T, Matthews CJ, Blaxill JM, et al. Meta-analysis comparing 10-year mortality following percutaneous coronary intervention or coronary artery bypass grafting in left main stem or multivessel coronary artery disease. Am J Cardiol. 2022;174:189\u201391. https:\/\/doi.org\/10.1016\/j.amjcard.2022.04.004.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2502_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcin.2021.10.026","volume":"15","author":"H Kawashima","year":"2022","unstructured":"Kawashima H, Serruys PW, Hara H, et al. 10-year all-cause mortality following percutaneous or surgical revascularization in patients with heavy calcification. JACC Cardiovasc Interv. 2022;15(2):193\u2013204. https:\/\/doi.org\/10.1016\/j.jcin.2021.10.026.","journal-title":"JACC Cardiovasc Interv"},{"key":"2502_CR7","doi-asserted-by":"crossref","unstructured":"McEntegart MB, Holm NR, Lindsay MM, Oldroyd KG, M\u00e4kikallio T, Hildick-Smith D, Erglis A, Kellerth T, Davidacius G, Menown IBA, et al. Sex-specific clinical outcomes after treatment of left main coronary artery disease. A NOBLE substudy. J Soc Cardiovasc Angiogr Intervent. 2022;1(4):100338","DOI":"10.1016\/j.jscai.2022.100338"},{"issue":"18","key":"2502_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.4244\/EIJ-D-21-00514","volume":"17","author":"RJ Van Geuns","year":"2022","unstructured":"Van Geuns RJ, Chun-Chin C, McEntegart MB, Merkulov E, Kretov E, Lesiak M, O\u2019Kane P, Hanratty CG, Bressollette E, Silvestri M, Wlodarczak A, Barragan P, Anderson R, Protopopov A, Peace A, Menown IBA, Rocchiccioli P, Onuma Y, Oldroyd KG. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. EuroIntervention. 2022;17(18):1467\u201376.","journal-title":"EuroIntervention"},{"issue":"11","key":"2502_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamacardio.2022.3032","volume":"7","author":"SR Mehta","year":"2022","unstructured":"Mehta SR, Wang J, Wood DA, et al. Complete revascularization vs. culprit lesion-only percutaneous coronary intervention for angina-related quality of life in patients with ST-segment elevation myocardial infarction: results from the complete randomized clinical trial. JAMA Cardiol. 2022;7(11):1091\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2022.3032.","journal-title":"JAMA Cardiol"},{"key":"2502_CR10","doi-asserted-by":"publisher","unstructured":"Romaguera R, Salinas P, Gomez-Lara J, et al. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. Eur Heart J. 2022;43(13):1320\u20131330. https:\/\/doi.org\/10.1093\/eurheartj\/ehab790","DOI":"10.1093\/eurheartj\/ehab790"},{"key":"2502_CR11","unstructured":"Salinas P. Two-year outcomes of the randomized second-generation drug-eluting stents in diabetes (SUGAR) trial. Presented at: TCT 2022. September 19, 2022. Boston, MA."},{"issue":"22","key":"2502_CR12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2022.09.007","volume":"80","author":"L Song","year":"2022","unstructured":"Song L, Xu B, Tu S, et al. 2-year outcomes of angiographic quantitative flow ratio-guided coronary interventions. J Am Coll Cardiol. 2022;80(22):2089\u2013101. https:\/\/doi.org\/10.1016\/j.jacc.2022.09.007.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2502_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2208335JonesD","volume":"387","author":"DW Park","year":"2022","unstructured":"Park DW, Kang DY, Ahn JM, et al. Routine functional testing or standard care in high-risk patients after PCI. N Engl J Med. 2022;387(10):905\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2208335JonesD.","journal-title":"N Engl J Med"},{"key":"2502_CR14","unstructured":"Jones D et al. The BYPASS-CTCA study: a randomised controlled trial assessing the value of computed tomography cardiac angiography (CTCA) in improving patient-related outcomes in patients with prior CABG undergoing invasive coronary angiography. Presented at: TCT 2022. September 19, 2022. Boston, MA."},{"issue":"18","key":"2502_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.122.061527","volume":"146","author":"G Gargiulo","year":"2022","unstructured":"Gargiulo G, Giacoppo D, Jolly SS, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation. 2022;146(18):1329\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061527.","journal-title":"Circulation"},{"key":"2502_CR16","doi-asserted-by":"crossref","unstructured":"Hammami R et al. Prevention of radial artery occlusion with rivaroxaban after transradial coronary procedures (RIVARAD). Presented at TCT 2022, Boston, MA, 2022.","DOI":"10.3389\/fcvm.2023.1160459"},{"issue":"12","key":"2502_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jcin.2022.04.032","volume":"15","author":"A Aminian","year":"2022","unstructured":"Aminian A, Sgueglia GA, Wiemer M, et al. Distal versus conventional radial access for coronary angiography and intervention: the DISCO RADIAL trial. JACC Cardiovasc Interv. 2022;15(12):1191\u2013201. https:\/\/doi.org\/10.1016\/j.jcin.2022.04.032.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"2502_CR18","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamacardio.2022.3399","volume":"7","author":"SS Jolly","year":"2022","unstructured":"Jolly SS, AlRashidi S, d\u2019Entremont MA, et al. Routine ultrasonography guidance for femoral vascular access for cardiac procedures: the UNIVERSAL randomized clinical trial. JAMA Cardiol. 2022;7(11):1110\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2022.3399.","journal-title":"JAMA Cardiol"},{"key":"2502_CR19","unstructured":"Momin A. Total arterial revascularization gives the best long-term survival over 20 years. Presented at: STS 2022. January 29, 2022. Ottowa, Canada."},{"key":"2502_CR20","unstructured":"Saadat S. Multi-arterial coronary artery bypass grafting practice patterns in the USA: a report from the STS database. Presented at: STS 2022. January 29, 2022. Ottowa, Canada."},{"issue":"21","key":"2502_CR21","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2022.08.787","volume":"80","author":"T Sharma","year":"2022","unstructured":"Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol. 2022;80(21):2054\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.787.","journal-title":"J Am Coll Cardiol"},{"key":"2502_CR22","unstructured":"G\u00e9n\u00e9reux P. The importance of pre-emptive TAVR in the future management of aortic stenosis. Presented at: TCT 2022. September 19, 2022. Boston, MA."},{"key":"2502_CR23","unstructured":"Garcia S, Bapat V, Depta JP, et al. Frequency and safety of bioprosthetic valve fracture in patients undergoing valve-in-valve TAVR for failed surgical valves using SAPIEN 3\/Ultra valves: insights from real-world data. Presented at: TCT 2022. Chicago, IL."},{"key":"2502_CR24","unstructured":"Tamm AR. JenaValve trilogy for treatment of aortic regurgitation: worldwide first results. Presented at: EuroPCR 2022. 2022; Paris, France."},{"issue":"6","key":"2502_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","volume":"146","author":"DW Park","year":"2022","unstructured":"Park DW, Ahn JM, Kang DY, et al. Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial. Circulation. 2022;146(6):466\u201379. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059512.","journal-title":"Circulation"},{"key":"2502_CR26","unstructured":"Giustino G. Predictors of mortality after successful transcatheter aortic valve replacement: from the GALILEO trial. Presented at: EuroPCR 2022. 2022. Paris, France."},{"key":"2502_CR27","unstructured":"Kaur A. Efficacy and safety outcomes of cerebral embolic protection devices during transcatheter aortic valve replacement: an updated meta-analysis. Presented at: TVT 2022. 2022. Chicago, IL"},{"issue":"14","key":"2502_CR28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa2204961","volume":"387","author":"SR Kapadia","year":"2022","unstructured":"Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic-valve replacement. N Engl J Med. 2022;387(14):1253\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2204961.","journal-title":"N Engl J Med"},{"key":"2502_CR29","unstructured":"Tang G, Mahoney P, von Bardeleben RS, et al. One-year outcomes in patients with secondary MR outside the COAPT criteria: the MitraClip Global Expand study. Presented at: TVT 2022. 2022. Chicago, IL."},{"issue":"24","key":"2502_CR30","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.jcin.2022.09.005","volume":"15","author":"DS Lim","year":"2022","unstructured":"Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15(24):2523\u201336. https:\/\/doi.org\/10.1016\/j.jcin.2022.09.005.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"2502_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4244\/EIJ-D-22-00437","volume":"18","author":"S Zahid","year":"2022","unstructured":"Zahid S, Ullah W, Hashem AM, et al. Transcatheter valve-in-valve implantation versus redo surgical mitral valve replacement in patients with failed mitral bioprostheses. EuroIntervention. 2022;18(10):824\u201335. https:\/\/doi.org\/10.4244\/EIJ-D-22-00437.","journal-title":"EuroIntervention"},{"key":"2502_CR32","unstructured":"Hahn R. Transcatheter tricuspid valve repair: CLASP TR study one-year results. Presented at: EuroPCR 2022. 2022. Paris, France."},{"key":"2502_CR33","unstructured":"Baldus S. 30-day outcomes for transcatheter tricuspid repair: TriCLASP post-market study. Presented at: EuroPCR 2022. 2022. Paris, France."},{"key":"2502_CR34","unstructured":"Lurz P. Real-world outcomes for tricuspid edge-to-edge repair: initial 30-day results from the TriClip bRIGHT study. Presented at: EuroPCR 2022. 2022. Paris, France."},{"key":"2502_CR35","doi-asserted-by":"publisher","unstructured":"Sommer RJ, Aboulhosn JA. New SCAI guidelines: trying to close the holes in the PFO literature. JSCAI. 2022;1 (4):100039. https:\/\/doi.org\/10.1016\/j.jscai.2022.100039","DOI":"10.1016\/j.jscai.2022.100039"},{"key":"2502_CR36","doi-asserted-by":"crossref","unstructured":"Lakkireddy D. 3-year outcomes from the Amplatzer Amulet left atrial appendage occluder randomized controlled trial (Amulet IDE). Presented at: TCT 2022. September 17, 2022. Boston, MA.","DOI":"10.1016\/j.jcin.2023.06.022"},{"issue":"21","key":"2502_CR37","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.jcin.2022.09.002","volume":"15","author":"MJ Price","year":"2022","unstructured":"Price MJ, Friedman DJ, Du C, et al. Comparative safety of transcatheter LAAO with the first-generation watchman and next-generation watchman FLX devices. JACC Cardiovasc Interv. 2022;15(21):2115\u201323. https:\/\/doi.org\/10.1016\/j.jcin.2022.09.002.","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"2502_CR38","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","volume":"79","author":"J Freeman","year":"2022","unstructured":"Freeman J, Higgins A, Wang Y, et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol. 2022;79(18):1785\u201398. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.047.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2502_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","volume":"147","author":"JS Hochman","year":"2023","unstructured":"Hochman JS, Anthopolos R, Reynolds HR, et al. Survival after invasive or conservative management of stable coronary disease. Circulation. 2023;147(1):8\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062714.","journal-title":"Circulation"},{"key":"2502_CR40","doi-asserted-by":"publisher","unstructured":"McCune C, McKavanagh P, Menown IB. A review of the key clinical trials of 2015: results and implications. Cardiol Ther. 2016;5(2):109\u2013132. https:\/\/doi.org\/10.1007\/s40119-016-0063-5. Epub 2016 Jun 8. PMID: 27277596; PMCID: PMC5125106","DOI":"10.1007\/s40119-016-0063-5"},{"key":"2502_CR41","unstructured":"Douglas PS. Comparison of a precision care strategy with usual testing to guide management of stable patients with suspected coronary artery disease. Presented at: AHA 2022. November 6, 2022. Chicago, IL."},{"key":"2502_CR42","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jacc.2022.08.767","volume":"80","author":"G Batra","year":"2022","unstructured":"Batra G, Lindb\u00e4ck J, Becker RC, et al. Biomarker-based prediction of recurrent ischemic events in patients with acute coronary syndromes. J Am Coll Cardiol. 2022;80:1735\u201347.","journal-title":"J Am Coll Cardiol"},{"key":"2502_CR43","unstructured":"Shinke T. Impact of underlying causes of acute coronary syndrome on 1-year outcomes after percutaneous coronary intervention. Presented at: TCT 2022. September 19, 2022. Boston, MA."},{"key":"2502_CR44","unstructured":"Vranckx P. Management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus prolonged DAPT regimen. Presented at: EuroPCR 2022. May 17, 2022. Paris, France."},{"key":"2502_CR45","unstructured":"Bhatt DL. Bentracimab immediately and significantly reverses the antiplatelet effects of ticagrelor in older people. Presented at: ACC 2022. April 2, 2022. Washington, DC."},{"key":"2502_CR46","doi-asserted-by":"publisher","unstructured":"Aggarwal D, Bhatia K, Chunawala ZS, et al. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open. 2022;2(2):oeac019. Published 2022. https:\/\/doi.org\/10.1093\/ehjopen\/oeac019","DOI":"10.1093\/ehjopen\/oeac019"},{"issue":"3","key":"2502_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.122.062762","volume":"147","author":"H Wu","year":"2023","unstructured":"Wu H, Xu L, Zhao X, et al. Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, endpoint-blinded. Noninferiority Trial Circ. 2023;147(3):212\u201322. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062762.","journal-title":"Noninferiority Trial Circ"},{"key":"2502_CR48","doi-asserted-by":"publisher","unstructured":"Rao SV, Kirsch B, Bhatt DL, et al. A Multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction [published correction appears in circulation. 2022 Dec 6;146(23):e330]. Circulation. 2022;146(16):1196\u20131206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061612","DOI":"10.1161\/CIRCULATIONAHA.122.061612"},{"issue":"10357","key":"2502_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4.","journal-title":"Lancet"},{"issue":"10366","key":"2502_CR50","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(22)01999-7.","journal-title":"Lancet"},{"key":"2502_CR51","unstructured":"Yang Y. The impact of Chinese herbal medicine tongxinluo in patients with acute myocardial infarction: results from the CTS-AMI trial. Presented at AHA 2022. November 6, 2022. Chicago, IL."},{"issue":"13","key":"2502_CR52","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jacc.2022.07.019","volume":"80","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhu H, Hou X, et al. Randomized trial of left bundle branch vs. biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol. 2022;80(13):1205\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.019.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2502_CR53","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.hrthm.2022.04.023","volume":"19","author":"P Vijayaraman","year":"2022","unstructured":"Vijayaraman P, Zalavadia D, Haseeb A, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. Heart Rhythm. 2022;19(8):1263\u201371. https:\/\/doi.org\/10.1016\/j.hrthm.2022.04.023.","journal-title":"Heart Rhythm"},{"issue":"8","key":"2502_CR54","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.hrthm.2022.04.024","volume":"19","author":"P Vijayaraman","year":"2022","unstructured":"Vijayaraman P, Herweg B, Verma A, et al. Rescue left bundle branch area pacing in coronary venous lead failure or nonresponse to biventricular pacing: results from International LBBAP Collaborative Study Group. Heart Rhythm. 2022;19(8):1272\u201380. https:\/\/doi.org\/10.1016\/j.hrthm.2022.04.024.","journal-title":"Heart Rhythm"},{"issue":"40","key":"2502_CR55","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1093\/eurheartj\/ehac445","volume":"43","author":"M Jastrz\u0119bski","year":"2022","unstructured":"Jastrz\u0119bski M, Kie\u0142basa G, Cano O, et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study. Eur Heart J. 2022;43(40):4161\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac445. (PMID: 35979843).","journal-title":"Eur Heart J"},{"key":"2502_CR56","doi-asserted-by":"crossref","unstructured":"Carina Blomstr\u00f6m-Lundqvist, Vassil Traykov, Paola Anna Erba et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections\u2014endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).\u00a0Eur Heart J. 2020; 41(21):2012\u20132032","DOI":"10.1093\/eurheartj\/ehaa010"},{"key":"2502_CR57","doi-asserted-by":"publisher","unstructured":"Khubrani R, Alghamdi AS, Alsubaie AA, Alenazi T, Almutairi A, Alsunaydi F. Rate of cardiovascular implantable electronic device-related infection at a tertiary hospital in saudi arabia: a retrospective cohort study. Cureus. 2022;14(7):e27078. Published 2022. https:\/\/doi.org\/10.7759\/cureus.27078","DOI":"10.7759\/cureus.27078"},{"key":"2502_CR58","unstructured":"Knops RE, Pepplinkhuizen S, Delnoy PPHM et al. Device-related complications in the subcutaneous and transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J. 2022."},{"issue":"1","key":"2502_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.048728","volume":"143","author":"MR Gold","year":"2021","unstructured":"Gold MR, Lambiase PD, El-Chami MF, et al. Primary results from the understanding outcomes With the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial. Circulation. 2021;143(1):7\u201317.","journal-title":"Circulation"},{"key":"2502_CR60","unstructured":"Healey J. The ATLAS trial: avoid transvenous leads in appropriate subjects. Presented at: HRS 2022. April 30, 2022. San Francisco"},{"issue":"27","key":"2502_CR61","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/eurheartj\/ehac053","volume":"43","author":"M Hadwiger","year":"2022","unstructured":"Hadwiger M, Dagres N, Haug J, et al. Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project. Eur Heart J. 2022;43(27):2591\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehac053.","journal-title":"Eur Heart J"},{"key":"2502_CR62","unstructured":"Aktas MK. The benefit of an implantable cardioverter-defibrillator in heart failure patients treated with empagliflozin: an analysis from the EMPEROR-Reduced trial. Presented at: HRS 2022. 2022; San Francisco, CA."},{"key":"2502_CR63","doi-asserted-by":"crossref","unstructured":"Samuel M, et al. Reduction in shock burden with catheter ablation versus escalated antiarrhythmic drug therapy: insights from the VANISH trial. News from ventricular ablation, EHRA 2022, 3\u20135 April, Copenhagen, Denmark","DOI":"10.1093\/europace\/euac053.364"},{"key":"2502_CR64","doi-asserted-by":"crossref","unstructured":"Dagres N, et al. Cardiac magnetic resonance imaging for prediction of risk for sudden cardiac death after myocardial infarction, the updated PROFID clinical prediction model. Late-breaking science 1, EHRA 2022, 3\u20135 April, Copenhagen, Denmark","DOI":"10.55788\/d4d68d85"},{"key":"2502_CR65","unstructured":"Jons C. BIO|GUARD-MI: biomonitoring in patients with preserved left ventricular function after diagnosed myocardial infarction. Presented at: ACC 2022. April 4, 2022."},{"key":"2502_CR66","doi-asserted-by":"publisher","unstructured":"Guo Y, Zhang H, Lip GYH; mAF-App II Trial investigators. Consumer-led screening for atrial fibrillation: a report from the mAFA-II trial long-term extension cohort. JACC Asia. 2022;2(6):737\u2013746. Published 2022 Nov 1. https:\/\/doi.org\/10.1016\/j.jacasi.2022.07.006","DOI":"10.1016\/j.jacasi.2022.07.006"},{"issue":"9","key":"2502_CR67","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41591-022-01979-w","volume":"28","author":"KD Rizas","year":"2022","unstructured":"Rizas KD, Freyer L, Sappler N, et al. Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med. 2022;28(9):1823\u201330. https:\/\/doi.org\/10.1038\/s41591-022-01979-w.","journal-title":"Nat Med"},{"key":"2502_CR68","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ahj.2022.09.007","volume":"254","author":"EP Zeitler","year":"2022","unstructured":"Zeitler EP, Bunch TJ, Khanna R, Fan X, Iglesias M, Russo AM. Comparative risk of dementia among patients with atrial fibrillation treated with catheter ablation versus anti-arrhythmic drugs. Am Heart J. 2022;254:194\u2013202. https:\/\/doi.org\/10.1016\/j.ahj.2022.09.007.","journal-title":"Am Heart J"},{"key":"2502_CR69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jacc.2021.11.035","volume":"79","author":"RE Harskamp","year":"2022","unstructured":"Harskamp RE, Fanaroff AC, Lopes RD, et al. Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous coronary intervention. J Am Coll Cardiol. 2022;79:417\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"2502_CR70","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al., on behalf of the INVICTUS Investigators. Rivaroxaban in Rheumatic Heart Disease\u2013Associated Atrial Fibrillation. N Engl J Med 2022;387:978\u201388.","DOI":"10.1056\/NEJMc2213437"},{"key":"2502_CR71","doi-asserted-by":"publisher","unstructured":"Castrej\u00f3n-Castrej\u00f3n S, Mart\u00ednez Cossiani M, J\u00e1uregui-Abularach M, et al. Multicenter prospective comparison of conventional and high-power short duration radiofrequency application for pulmonary vein isolation: the high-power short-duration radiofrequency application for faster and safer pulmonary vein ablation (POWER FAST III) trial [published online ahead of print, 2023 Feb 18]. J Interv Card Electrophysiol. 2023. https:\/\/doi.org\/10.1007\/s10840-023-01509-9","DOI":"10.1007\/s10840-023-01509-9"},{"key":"2502_CR72","doi-asserted-by":"crossref","unstructured":"Lemoine M, et al. Pulmonary vein isolation by pulsed-field ablation induces smaller neurocardiac damage than cryoballoon ablation. Atrial fibrillation and ablation, EHRA 2022, 3\u20135 April, Copenhagen, Denmark","DOI":"10.55788\/ae6d06cb"},{"key":"2502_CR73","doi-asserted-by":"crossref","unstructured":"Kueffer T, et al. Pulsed field ablation of atrial fibrillation: Recurrence rate after first pulmonary vein isolation and first insights into durability and redo procedures. Poster Session, EHRA 2022, 3\u20135 April.","DOI":"10.1093\/europace\/euac053.148"},{"issue":"2","key":"2502_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2212540","volume":"388","author":"JG Andrade","year":"2023","unstructured":"Andrade JG, Deyell MW, Macle L, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023;388(2):105\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2212540.","journal-title":"N Engl J Med"},{"key":"2502_CR75","unstructured":"Piccini JP. Efficacy and safety of botulinum toxin type A for the prevention of postoperative atrial fibrillation in cardiac surgery patients: results from the phase 2 NOVA study. Presented at: AHA 2022. 2022; Chicago"},{"key":"2502_CR76","doi-asserted-by":"publisher","unstructured":"Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022;15(12):e010915. https:\/\/doi.org\/10.1161\/CIRCEP.122.010915","DOI":"10.1161\/CIRCEP.122.010915"},{"issue":"5","key":"2502_CR77","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1007\/s12325-021-01711-z","volume":"38","author":"A Kearney","year":"2021","unstructured":"Kearney A, Linden K, Savage P, Menown IBA. Advances in clinical cardiology 2020: a summary of key clinical trials. Adv Ther. 2021;38(5):2170\u2013200. https:\/\/doi.org\/10.1007\/s12325-021-01711-z.","journal-title":"Adv Ther"},{"issue":"3","key":"2502_CR78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2022.11016","volume":"328","author":"GD Lewis","year":"2022","unstructured":"Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of Omecamtiv Mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA. 2022;328(3):259\u201369. https:\/\/doi.org\/10.1001\/jama.2022.11016.","journal-title":"JAMA"},{"issue":"41","key":"2502_CR79","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401.","journal-title":"Eur Heart J"},{"issue":"22","key":"2502_CR80","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","volume":"79","author":"L Ghazi","year":"2022","unstructured":"Ghazi L, Yamamoto Y, Riello R, et al. Electronic alerts to improve heart failure therapy in outpatient practice. J Am Coll Cardiol. 2022;79(22):2203\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.338.","journal-title":"J Am Coll Cardiol"},{"issue":"387","key":"2502_CR81","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"26","author":"JM Castellano","year":"2022","unstructured":"Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;26(387):967\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2208275.","journal-title":"N Engl J Med"},{"key":"2502_CR82","doi-asserted-by":"publisher","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"2502_CR83","doi-asserted-by":"publisher","unstructured":"EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"2502_CR84","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"387","key":"2502_CR85","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"27","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;27(387):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"387","key":"2502_CR86","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"26","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;26(387):1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094.","journal-title":"N Engl J Med"},{"issue":"10367","key":"2502_CR87","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400(10367):1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1.","journal-title":"The Lancet"},{"key":"2502_CR88","doi-asserted-by":"publisher","unstructured":"Kalra PR, Cleland JGF, Petrie MC et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083\u20139.","DOI":"10.1016\/S0140-6736(22)02083"},{"issue":"2","key":"2502_CR89","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2502_CR90","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"key":"2502_CR91","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","volume":"349","author":"DA Rider","year":"2022","unstructured":"Rider DA, Eisermann M, L\u00f6ffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.029.","journal-title":"Atherosclerosis"},{"issue":"10355","key":"2502_CR92","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"CTT Collaboration","year":"2022","unstructured":"Collaboration CTT. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet. 2022;400(10355):832\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(22)01545-8.","journal-title":"The Lancet"},{"key":"2502_CR93","doi-asserted-by":"publisher","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022; 11;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"issue":"10359","key":"2502_CR94","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022;400(10359):1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(22)01657-9.","journal-title":"The Lancet"},{"issue":"10367","key":"2502_CR95","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. The Lancet. 2022;400(10367):1927\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7.","journal-title":"The Lancet"},{"issue":"10339","key":"2502_CR96","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0140-6736(22)00325-7","volume":"399","author":"Y Sun","year":"2022","unstructured":"Sun Y, Mu J, Wang DW, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022;399(10339):1964\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(22)00325-7.","journal-title":"Lancet"},{"key":"2502_CR97","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41371-020-00469-1","volume":"35","author":"CLB Ho","year":"2021","unstructured":"Ho CLB, Chowdhury EK, Doust J, et al. The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review. J Hum Hypertens. 2021;35:308\u201314.","journal-title":"J Hum Hypertens"},{"key":"2502_CR98","doi-asserted-by":"crossref","unstructured":"Mackenzie IS, Rogers A, Poulter NR, et al., on behalf of the TIME study group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME Study): a prospective, randomized, open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417\u201325.","DOI":"10.1016\/S0140-6736(22)01786-X"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02502-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02502-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T17:25:24Z","timestamp":1702229124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02502-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2502"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02502-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}